Newer-generation GLP-1 RAs, such as high-dose once-weekly injectable semaglutide (up to 2.0 mg in T2D and 2.4 mg in weight management) [127,128], once-daily oral semaglutide (up to 50 mg in weight management [129]) and the GLP-1/GIP dual RA tirzepatide [130,131,132], have demonstrated significant reductions in glycated hemoglobin and body weight. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.